Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

22.95 +1.62 (+7.59%)
Streaming Delayed Price Updated: 2:20 PM EDT, Jun 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 833,124
Open 20.91
Bid (Size) 22.92 (4)
Ask (Size) 22.98 (2)
Prev. Close 21.33
Today's Range 20.64 - 24.39
52wk Range 11.25 - 56.66
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
-2.26%
-2.26%
1 Month
+4.22%
+4.22%
3 Month
-25.68%
-25.68%
6 Month
+16.08%
+16.08%
1 Year
-58.43%
-58.43%

More News

Read More
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
AKRO STOCKHOLDERS - Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Akero Therapeutics, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Via Benzinga
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Via Investor's Business Daily
AKRO INVESTOR ALERT: Kirby McInerney LLP Notifies Akero Therapeutics, Inc. (AKRO) Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
From Kirby McInerney LLP
Via Business Wire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
The Week Ahead: What's Next
Via Talk Markets
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Kirby McInerney LLP Reminds Akero Therapeutics, Inc. (AKRO) Investors of Class Action Filing and Encourages Investors to Contact the Firm
From Kirby McInerney LLP
Via GlobeNewswire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
AKRO EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
From The Rosen Law Firm, P.A.
Via Business Wire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.